MARKET

REPL

REPL

Replimune Group
NASDAQ

Real-time Quotes | Nasdaq Last Sale

35.50
+0.11
+0.31%
Closed 16:00 05/06 EDT
OPEN
36.11
PREV CLOSE
35.39
HIGH
36.11
LOW
34.61
VOLUME
392.24K
TURNOVER
--
52 WEEK HIGH
54.85
52 WEEK LOW
17.26
MARKET CAP
1.65B
P/E (TTM)
-20.3648
1D
5D
1M
3M
1Y
5Y
BTIG Maintains a Buy Rating on Replimune Group (REPL)
BTIG analyst Thomas Shrader maintained a Buy rating on Replimune Group (REPL) yesterday and set a price target of $60.00. The company's shares closed last
SmarterAnalyst · 1d ago
Replimune shares rise 9% following positive clinical trial updates for lead candidate
Replimune (REPL) shares are up 9% after the company issued positive updates on two clinical trials of its lead candidate.The company said it was amending the phase 2 CERPASS trial
Seekingalpha · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 1d ago
BRIEF-Replimune Provides A Regulatory Update For Its Registration- Directed Clinical Trials Evaluating RP1 In Combination With Libtayo
reuters.com · 2d ago
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its re...
GlobeNewswire · 2d ago
Analysts See Plenty of Upside for Replimune
GuruFocus News · 04/22 18:19
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
WOBURN, Apr 21, 2021 (GLOBE NEWSWIRE via COMTEX) -- WOBURN, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology...
GlobeNewswire · 04/21 12:00
Insider Trends: Insider Sale at Replimune Group Slowing 90-Days of Buying
MT Newswires · 04/19 18:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REPL. Analyze the recent business situations of Replimune Group through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REPL stock price target is 56.30 with a high estimate of 67.00 and a low estimate of 48.00.
EPS
Institutional Holdings
Institutions: 136
Institutional Holdings: 35.15M
% Owned: 75.61%
Shares Outstanding: 46.49M
TypeInstitutionsShares
Increased
46
11.06M
New
43
2.20M
Decreased
15
967.53K
Sold Out
10
4.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.30%
Key Executives
Chairman/Independent Director
Dieter Weinand
President/Director
Robert Coffin
Chief Executive Officer/Director
Philip Astley-Sparke
Chief Executive Officer/Treasurer/Secretary
philip Astley-Sparke
Chief Financial Officer/Chief Compliance Officer/Treasurer/Secretary
Jean Franchi
Chief Operating Officer
Colin Love
Other
Pamela Esposito
Other
Sushil Patel
Other
Andrea Pirzkall
Independent Director
Kapil Dhingra
Independent Director
Hyam Levitsky
Independent Director
Tanya Lewis
Independent Director
Paolo Pucci
Independent Director
Jason Rhodes
Independent Director
Joseph Slattery
Independent Director
Sander Slootweg
Independent Director
Otello Stampacchia
No Data
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1, RP2, and RP3. The Company is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

Webull offers kinds of Replimune Group Inc stock information, including NASDAQ:REPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPL stock methods without spending real money on the virtual paper trading platform.